JUBLPHARMA Jubilant Pharmova Q4 FY26 results (Jan–Mar 2026) and concall
Jubilant Pharmova reported strong revenue growth for Q4 and Full Year FY26, driven by key segments like CDMO, radiopharma, and generics. However, profitability was impacted by supply shortages in SPECT products and under-absorption of costs at the CMO Montreal facility, leading to margin compression. The company anticipates a stronger H2 FY27 with stabilization of Montreal production and commercialization of new CDMO lines, while targeting net debt zero by FY2030.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 15.8%, net profit up 320.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 61 | 56 | 61 | 60 | 66 +8% | 67 +20% | 70 +16% |
| EBITDA | 10 | 10 | 11 | 10 | 12 +18% | 12 +22% | 15 +33% |
| Net profit | 11 | 5 | 14 | 6 | -6 −161% | 7 +25% | 57 +321% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
